Dual targeting of EZH2 and HDAC in haematological malignancies
Presented by Thomas Slegers & Dr Marlies Vanden Bempt (KU Leuven, Belgium)
Thomas Slegers, a doctoral researcher, and Dr Marlies Vanden Bempt, a postdoctoral researcher, both from KU Leuven, presented their research on the dual targeting of EZH2 and HDAC in haematological malignancies. Both EZH2 and HDAC inhibitors are currently utilized in clinical practice for treating various haematological cancers. Previous studies have shown strong synergistic effects between EZH2 degradation and HDAC inhibition in peripheral T cell lymphoma. Their ongoing research aims to demonstrate the broad applicability of combined EZH2 and HDAC targeting for haematological cancers and to elucidate the mechanism of action underlying the synergism of this combination treatment.
References:
Vanden Bempt A, EHA2024. #P360
With the educational support of:
